** Biomea Fusion's shares fall ~5% to $4.10 premarket as Truist Securities cuts to "hold" from "buy"
** US FDA placed clinical hold on studies of Biomea's diabetes drug on June 6 due to liver toxicity concerns
** Truist says lack of details on those concerns makes its tough to estimate a resolution timeline and adds that cash runway concerns are keeping investors on the sidelines
** Expects stock to trade in a band until FDA hold is lifted
** Stock has sunk 62% in 2 sessions since the ruling
** Truist does not assign a PT due to recent volatility
** Now 3 brokers, incl Truist, rate BMEA 'hold' and 5 'buy'/'strong buy' - LSEG data
** 4 brokers have changed their PTs since the FDA; their PTs are $5, $10, $21 and $45 -LSEG data
(Reporting by Purvi Agarwal in Bengaluru)
((Purvi.Agarwal@thomsonreuters.com))
Comments